Aardvark reports ARD-201 preclinical data: 19% weight loss in mice; plans two Phase 2 trials

Aardvark Therapeutics, Inc.

ARD-201 monotherapy achieved ~19% body weight reduction in DIO mice after 30 days.
ARD-201 attenuated weight regain after tirzepatide withdrawal; combo with low-dose tirzepatide outperformed high-dose tirzepatide alone.
Phase 2 POWER trial (2H 2025) targets weight regain prevention in patients discontinuing GLP-1RA therapy.
Phase 2 STRENGTH trial (1H 2026) to test monotherapy and combination with GLP-1RA, replacing prior EMPOWER trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.